Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 5, Issue 4, Pages 298-303Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ml4003309
Keywords
NSCLC; EGFR; c-Met; kinase inhibitor; acquired resistance
Categories
Funding
- [NKFP_07_A2-NANODRUG]
Ask authors/readers for more resources
Activating mutations in the epidermal growth factor receptor (EGER) have been identified in a subset of non-small cell lung cancer (NSCLC), which is one of the leading cancer types worldwide. Application of EGFR tyrosine kinase inhibitors leads to acquired resistance by secondary EGFR mutations or by amplification of the hepatocyte growth factor receptor (c-Met) gene. Although several EGFR and c-Met inhibitors have been reported, potent dual EGFR/c-Met inhibitors, which can overcome this latter resistance mechanism, have hitherto not been published and have not reached clinical trials. In the present study we have identified dual EGFR/c-Met inhibitors and designed novel N-[4-(quinolin-4-yloxy)-phenyl]-biarylsulfonamide derivatives, which inhibit the c-Met receptor and both the wild-type and the activating mutant EGFR kinases in nanomolar range. We have demonstrated by Western blot analysis that compound 10 inhibits EGFR and c-Met phosphorylation at cellular level and effectively inhibits viability of the NSCLC cell lines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available